Manish Khairnar *
Siddhesh Marda
Precision medicine represents a transformative shift in healthcare, aiming to tailor treatment and prevention strategies to the unique biological makeup of each individual. This approach recognizes that diseases, particularly complex disorders such as cancer, autoimmune conditions, and metabolic syndromes, are not monolithic entities but rather heterogeneous processes shaped by genomic, molecular, environmental, and lifestyle factors. Central to the success of precision medicine is the ability to unravel this heterogeneity at multiple biological scales, a task increasingly enabled by multi-omics technologies.1 Multi-omics refers to the integrative analysis of diverse omics data types, including genomics, epigenomics, transcriptomics, proteomics, metabolomics, and others, to provide a comprehensive view of cellular and physiological processes. Each omics layer captures distinct dimensions of biological regulation: the genome provides the blueprint, the epigenome modulates gene accessibility, the transcriptome reflects dynamic gene activity, the proteome encodes functional effectors, and the metabolome represents the biochemical state of the cell. When combined, these layers offer synergistic insights into disease mechanisms, treatment response, and systems-level interactions that cannot be inferred from any single modality alone.2 Historically, the analysis of omics data has been siloed, with each layer investigated independently due to technological limitations, data incompatibility, and lack of integrative frameworks. Genomic studies have identified mutations linked to disease susceptibility and potential therapy targets, while transcriptomics has revealed gene expression signatures associated with prognosis. However, such isolated analyses often failed to account for downstream regulatory events, post-translational modifications, and metabolic alterations that critically influence phenotype. The emergence of integrative bioinformatics tools, advances in sequencing and mass spectrometry, and the establishment of public consortia such as TCGA, CPTAC, and ICGC have collectively catalysed a shift toward truly multi-dimensional analysis.3 In parallel, novel experimental technologies—most notably single-cell omics and spatial transcriptomics—have enabled the dissection of molecular heterogeneity at unprecedented resolution. These tools enable researchers to capture cell-type-specific and location-specific molecular profiles, revealing how the tumour microenvironment, immune landscape, and intercellular interactions influence treatment outcomes. Such insights are increasingly informing the design of adaptive therapies, combination regimens, and biomarker-driven clinical trials.4 This review aims to provide an in-depth synthesis of the current state and future directions of multi-omics in precision medicine. We begin by examining the biological contributions and limitations of individual omics layers, followed by a discussion of their interconnections through systems biology and trans-omics approaches. Subsequent sections explore the landscape of computational integration strategies, AI-driven predictive models, and case studies where multi-omics has informed clinical decision-making. Special emphasis is placed on single-cell and spatial technologies, the microbiome, and time-series omics, as well as the ethical, legal, and social dimensions of implementing these tools in real-world settings. By offering a holistic overview grounded in both mechanistic biology and translational science, this review underscores how multi-omics is poised to drive the next generation of predictive, preventative, and personalized healthcare.
10.5281/zenodo.15831126